Abstract
To explore the cost-effectiveness of quetiapine, aripiprazole or olanzapine in Russian Federation (RF) patients with bipolar disorder (BPD) depression episodes. A cost-effectiveness analysis (CEA) was developed to estimate the cost-effectiveness of quetiapine compared with aripiprazole or olanzapine. CEA was undertaken from RF health care perspective using discount rate of 5%. The time horizon of the analysis was ne year for using preventive relapse rates and five years for QALY. Direct health care expenses associated with bipolar disorder and resulting follow-up costs were calculated using general tariff agreement of Russian obligatory insurance system and official national statistics. For reference, accepted exchange rate was 1 EUR = 40 RUB. Taking into account rates of prevented relapse following cost-effectiveness ratios (CER) were obtained: 156,915 RUB (3,923 EUR) in quetiapine group, 429,362 RUB (10,734 EUR) in aripiprazole group and 221,879 RUB (5,547 EUR) in olanzapine group. Using QALY values CER were accounted for: 185,236 RUB (4,631 EUR) in quetiapine group, 478,433 RUB (11,961 EUR) in aripiprazole group and 254,100 RUB (6,353 EUR) in olanzapine group. Quetiapine in the treatment of BPD depression episodes is a dominant compared with aripiprazole or olanzapine.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
